Opportunity Information: Apply for RFA IP 15 002
Apply for RFA IP 15 002
- The Centers for Disease Control and Prevention in the health sector is offering a public funding opportunity titled "US Platform to Measure Influenza Vaccine Effectiveness against Laboratory confirmed Influenza associated" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.185 Immunization Research, Demonstration, Public Information and EducationTraining and Clinical Skills Improvement Projects.
- This funding opportunity was created on Jan 30, 2015 and posted on Jan 13, 2015.
- Applicants must submit their applications by Mar 3, 2015. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $11,600,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $300,000.00 in funding.
- The number of recipients for this funding is limited to 4 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Eligibility Category State governments County governments City or township governments Special district governments Independent school districts Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education For profit organizations other than small businesses Small businesses The following types of Higher Education Institutions are always encouraged to apply for CDC support as Public or Private Institutions of Higher Education Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Tribally Controlled Colleges and Universities (TCCUs) Alaska Native and Native Hawaiian Serving Institutions Nonprofits Other Than Institutions of Higher Education Nonprofits (Other than Institutions of Higher Education) Governments Eligible Agencies of the Federal Government U.S. Territory or Possession Other Native American tribal organizations (other than Federally recognized tribal governments) Faith based or Community based Organizations Regional Organizations Bona Fide Agents a Bona Fide Agent is an agency/organization identified by the state as eligible to submit an application under the state eligibility in lieu of a state application. If applying as a bona fide agent of a state or local government, a legal, binding agreement from the state or local government as documentation of the status is required. Attach with Other Attachment Forms when submitting via www.grants.gov. Foreign Organizations are not eligible to apply. Foreign components of U.S. Organizations are not eligible to apply.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This CDC grant opportunity (Funding Opportunity Number RFA IP 15 002) supports the creation and long-term operation of a US-based network designed to measure how well seasonal influenza vaccines prevent serious illness requiring hospitalization among adults. The core public health purpose is to generate accurate, annual estimates of influenza vaccine effectiveness (VE) specifically against laboratory-confirmed, influenza-associated hospitalizations. By building a sustainable multi-institution platform, the program aims to improve the evidence base used to assess vaccine performance from season to season and to inform vaccination policy and preparedness.
Funded sites are expected to work as part of a coordinated network of US institutions that can reliably access hospitalization data and systematically enroll adult patients who are hospitalized with acute respiratory illness (ARI). The operational model centers on enrolling eligible hospitalized adults, collecting clinical and epidemiologic information, and then confirming influenza infection using sensitive laboratory-based molecular assays (for example, molecular PCR-type testing rather than less sensitive approaches). Using these results, awardees will estimate vaccine effectiveness with a test-negative study design, a common method for influenza VE work where vaccination status is compared between those who test positive for influenza and those with similar symptoms who test negative. The emphasis on laboratory confirmation and a standardized analytic approach is intended to produce robust, comparable VE estimates each year across participating institutions.
The award mechanism is a cooperative agreement, indicating substantial federal involvement and collaboration beyond a typical grant. The activity category is health, and the program anticipated making about four awards. Total estimated funding for the opportunity is approximately $11.6 million, with individual award amounts listed in a relatively narrow range (award floor $275,000 and award ceiling $300,000), reflecting an intent to fund multiple sites at similar levels and likely support consistent core activities across the network. There is no cost sharing or matching requirement.
Eligibility is broad across US-based organizations, reflecting the need for clinical, laboratory, and data capabilities that may be housed in different types of institutions. Eligible applicants include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; nonprofit organizations including those with 501(c)(3) status; for-profit organizations (other than small businesses) as well as small businesses; federally recognized tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; US territories or possessions; and eligible federal agencies. Faith-based and community-based organizations and regional organizations are also listed as eligible. Higher education institutions serving historically underserved populations (including HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, and Alaska Native and Native Hawaiian serving institutions) are explicitly encouraged to apply. A state or local government may also apply through a bona fide agent, but that requires a legal, binding agreement documenting the agent status. Foreign organizations and foreign components of US organizations are not eligible.
Administratively, the opportunity was posted January 13, 2015, with an original and final closing date of March 3, 2015, and an archive date of April 2, 2015. The program is administered by the Centers for Disease Control and Prevention (CDC) under CFDA 93.185 (Immunization Research, Demonstration, Public Information and Education; Training and Clinical Skills Improvement Projects). For applicants needing assistance accessing the full announcement materials, the CDC Procurement and Grants Office (PGO) provided contact support by phone at 770-488-2700 or email at pgotim@cdc.gov.
Overall, the opportunity is best understood as infrastructure-plus-evidence generation: it funds a coordinated national platform capable of enrolling and testing hospitalized adults with ARI, linking clinical and hospitalization data, and producing standardized, annual VE estimates based on lab-confirmed influenza outcomes. The expected result is a durable, repeatable surveillance-and-evaluation capability that can track vaccine performance against the most severe adult outcomes over time.
FAQs: CDC Funding Opportunity RFA IP 15 002 (Seasonal Influenza Vaccine Effectiveness Network)
1) What is this CDC grant opportunity about?
This funding opportunity (RFA IP 15 002) supports the creation and long-term operation of a U.S.-based network that measures how well seasonal influenza vaccines prevent serious adult illness that results in hospitalization. The central public health goal is to generate accurate, annual estimates of influenza vaccine effectiveness (VE) against laboratory-confirmed, influenza-associated hospitalizations in adults.
2) What is the main outcome the network is expected to measure?
The network is designed to estimate vaccine effectiveness specifically against severe outcomes: laboratory-confirmed influenza infections that are associated with hospitalization among adults.
3) Why does the opportunity focus on hospitalized adults?
Based on the announcement description, the focus is on the most serious adult outcomes of seasonal influenza, particularly illnesses severe enough to require hospitalization, to strengthen the evidence used to assess vaccine performance season to season and to inform vaccination policy and preparedness.
4) What kind of network does CDC expect to fund?
CDC expects funded sites to work as part of a coordinated, multi-institution U.S. network. Participating institutions should be able to reliably access hospitalization data and systematically enroll adult patients hospitalized with acute respiratory illness (ARI).
5) What are funded sites expected to do?
Funded sites are expected to implement a consistent operational model that includes: enrolling eligible hospitalized adults with ARI, collecting clinical and epidemiologic information, confirming influenza infection using sensitive laboratory-based molecular assays, and producing annual VE estimates using a standardized analytic approach.
6) What is meant by enrolling adults hospitalized with acute respiratory illness (ARI)?
Within this opportunity, ARI refers to adults hospitalized with respiratory illness symptoms consistent with acute respiratory illness. These patients are systematically enrolled so influenza testing and data collection can be performed in a standardized way across sites.
7) How is influenza infection confirmed for the vaccine effectiveness analysis?
The network emphasizes laboratory confirmation using sensitive molecular assays (for example, molecular PCR-type testing) rather than less sensitive approaches. The intent is to ensure influenza status is determined accurately for VE calculations.
8) What study design will awardees use to estimate vaccine effectiveness?
Awardees will estimate vaccine effectiveness using a test-negative study design. Under this approach, vaccination status is compared between hospitalized adults who test positive for influenza and those with similar symptoms who test negative for influenza.
9) Why does the opportunity emphasize standardized laboratory and analytic methods?
The emphasis on lab confirmation and a standardized analytic approach is intended to produce robust and comparable VE estimates each year across participating institutions, improving the consistency of results from season to season.
10) What is the intended public health impact of the program?
The program is described as “infrastructure-plus-evidence generation.†It aims to build a sustainable platform that can repeatedly enroll and test hospitalized adults with ARI, link clinical and hospitalization data, and generate standardized annual VE estimates to support vaccine performance assessment and inform vaccination policy and preparedness.
11) What is the funding mechanism for this opportunity?
The award mechanism is a cooperative agreement, which indicates substantial federal involvement and collaboration beyond what is typical for a standard grant.
12) What is the activity category for this funding opportunity?
The activity category is health.
13) How many awards did CDC anticipate making?
The opportunity anticipated making about four awards.
14) What is the estimated total funding amount for the opportunity?
The total estimated funding is approximately $11.6 million.
15) What is the expected funding range per award?
Individual awards are listed in a relatively narrow range, with an award floor of $275,000 and an award ceiling of $300,000, suggesting multiple sites would be funded at similar levels to support consistent core activities across the network.
16) Is cost sharing or matching required?
No. The opportunity states there is no cost sharing or matching requirement.
17) Who is eligible to apply?
Eligibility is broad across U.S.-based organizations. Eligible applicants include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; nonprofit organizations (including 501(c)(3) organizations); for-profit organizations (including small businesses and other-than-small businesses); federally recognized tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; U.S. territories or possessions; and eligible federal agencies. Faith-based and community-based organizations and regional organizations are also listed as eligible.
18) Are institutions serving historically underserved populations encouraged to apply?
Yes. The opportunity explicitly encourages applications from higher education institutions serving historically underserved populations, including HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, and Alaska Native and Native Hawaiian serving institutions.
19) Can a state or local government apply through an agent?
Yes. A state or local government may apply through a bona fide agent, but the opportunity notes that a legal, binding agreement documenting the agent status is required.
20) Are foreign organizations eligible to apply?
No. Foreign organizations and foreign components of U.S. organizations are not eligible.
21) When was the opportunity posted, and what were the closing dates?
The opportunity was posted on January 13, 2015. The original and final closing date was March 3, 2015. The archive date was April 2, 2015.
22) Which federal agency administers this program?
The program is administered by the Centers for Disease Control and Prevention (CDC).
23) What is the CFDA number associated with this opportunity?
The opportunity is listed under CFDA 93.185: Immunization Research, Demonstration, Public Information and Education; Training and Clinical Skills Improvement Projects.
24) What kinds of capabilities does a participating site need, based on the description?
Based on the program description, participating sites should be able to access hospitalization data, systematically enroll eligible hospitalized adults with ARI, collect clinical and epidemiologic data, and perform (or otherwise ensure access to) sensitive molecular influenza testing to support standardized VE estimation.
25) Where can applicants get help accessing the full announcement materials?
Applicants needing assistance accessing the full announcement materials could contact the CDC Procurement and Grants Office (PGO) by phone at 770-488-2700 or by email at pgotim@cdc.gov.
Browse more opportunities from the same agency: Centers for Disease Control and Prevention
Browse more opportunities from the same category: Health
Next opportunity: OVW FY 2015 Transitional Housing Assistance Grants for Victims of Sexual Assault, Domestic Violence, Dating Violence, and Stalking
Previous opportunity: HAPET Collaborative Migratory Bird Research and Evaluation
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA IP 15 002
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA IP 15 002) also looked into and applied for these:
| Funding Opportunity |
|---|
| Increasing Participation of People with Disabilities in USAID Activities and Strengthen the Capacities of Disabled Peoples Organizations (DPOs). Apply for RFA 114 15 000006 Funding Number: RFA 114 15 000006 Agency: Georgia USAID Tbilisi Category: Health Funding Amount: $600,000 |
| Maternal Newborn and Child Health Activity Apply for RFA 611 15 000001 Funding Number: RFA 611 15 000001 Agency: Zambia USAID Lusaka Category: Health Funding Amount: $7,500,000 |
| Program Expansion Supplement for GH11 1109, Strengthening Local Capacity to Provide Sustainable HIV Related Care and Treatment Services in South Africa under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH11 11090501SUPP15 Funding Number: CDC RFA GH11 11090501SUPP15 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $24,000,000 |
| Analyze and Evaluate Potential Risk Factors for Amyotrophic Lateral Sclerosis (ALS) Apply for RFA TS 15 001 Funding Number: RFA TS 15 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $400,000 |
| R40 MCH Autism Secondary Data Analysis Studies Program Apply for HRSA 15 083 Funding Number: HRSA 15 083 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Quality Improvement Capacity for Impact Project Apply for HRSA 15 021 Funding Number: HRSA 15 021 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| NIGMS Program of Administrative Supplements for Equipment (Admin Supp) Apply for PA 15 089 Funding Number: PA 15 089 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Hospital Preparedness Program (HPP) and Public Health Emergency Preparedness (PHEP) Cooperative Agreements / PHEP Supplemental for Ebola Preparedness and Response Activities Apply for CDC RFA TP12 12010302SUPP15 Funding Number: CDC RFA TP12 12010302SUPP15 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $9,232,987 |
| NIAMS Rheumatic Diseases Research Resource based Centers (P30) Apply for RFA AR 16 002 Funding Number: RFA AR 16 002 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Stillbirth Risk Factor Pilot Project Centers for Birth Defects Research and Prevention (CBDRPs) Apply for RFA DD 15 004 Funding Number: RFA DD 15 004 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $300,000 |
| Drug Free Communities Support Program Apply for SP 15 001 Funding Number: SP 15 001 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $125,000 |
| Cooperative Agreement for Networking, Certifying, and Training Suicide Prevention Hotlines and Disaster Distress Helpline Apply for SM 15 007 Funding Number: SM 15 007 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $6,211,000 |
| Intramural NIGMS Postdoctoral Research Associate (PRAT) Program (FI2) Apply for PAR 15 094 Funding Number: PAR 15 094 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| National Fetal, Infant and Child Death Review Center Program Apply for HRSA 15 069 Funding Number: HRSA 15 069 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| FY15 Announcement of Anticipated Availability of Funds for One Family Planning Clinical Training Cooperative Agreement Apply for PA FPT 15 001 Funding Number: PA FPT 15 001 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $750,000 |
| Population based Diabetes in Youth Registry Apply for RFA DP 15 002 Funding Number: RFA DP 15 002 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $380,000 |
| Promoting Adolescent Health through School Based HIV/STD Prevention and School Based Surveillance Apply for CDC RFA PS13 130803CONT15 Funding Number: CDC RFA PS13 130803CONT15 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Domestic Ebola Supplement to Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) Building and Strengthening Epidemiology, Laboratory and Health Information Systems Capacity in State and Local Health Departments Apply for CK14 1401PPHFSUPP15 Funding Number: CK14 1401PPHFSUPP15 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Service Area Competition Additional Areas (SAC AA) GA KS LA MS MT PA SC TX and WA Apply for HRSA 15 141 Funding Number: HRSA 15 141 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Rural Health Value Program Apply for HRSA 15 072 Funding Number: HRSA 15 072 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA IP 15 002", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.